Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Riley

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 22, 2008
Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactionsDermot F McGinnity, Nigel J Waters, James Tucker, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 3, 2004
Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearanceDermot F McGinnity, Matthew G Soars, Richard A Urbanowicz, et al.
British Journal of Clinical Pharmacology|February 13, 2003
A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymologyMatthew G Soars, Harry V Gelboin, Kristopher W Krausz, et al.
Archives of Toxicology|May 7, 2020
The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and developmentPaul A Walker, Stephanie Ryder, Andrea Lavado, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 5, 2006
The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery settingCharles J O'Donnell, Ken Grime, Paul Courtney, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 17, 2012
The development, characterization, and application of an OATP1B1 inhibition assay in drug discoveryMatthew G Soars, Patrick Barton, Manfred Ismair, et al.
Pharmacology Research & Perspectives|October 8, 2016
Evaluation of a novel PXR-knockout in HepaRG<sup>™</sup> cellsBeth Williamson, Mathias Lorbeer, Michael D Mitchell, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 2, 2011
Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorptionStuart W Paine, Karelle Ménochet, Rebecca Denton, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 9, 2006
Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytesDermot F McGinnity, Amanda J Berry, Jane R Kenny, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 20, 2002
CYP3A4 active site volume modification by mutagenesis of leucine 211Stephen M Fowler, John M Taylor, Thomas Friedberg, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 22, 2008
Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactionsDermot F McGinnity, Nigel J Waters, James Tucker, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 3, 2004
Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearanceDermot F McGinnity, Matthew G Soars, Richard A Urbanowicz, et al.
British Journal of Clinical Pharmacology|February 13, 2003
A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymologyMatthew G Soars, Harry V Gelboin, Kristopher W Krausz, et al.
Archives of Toxicology|May 7, 2020
The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and developmentPaul A Walker, Stephanie Ryder, Andrea Lavado, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 5, 2006
The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery settingCharles J O'Donnell, Ken Grime, Paul Courtney, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 17, 2012
The development, characterization, and application of an OATP1B1 inhibition assay in drug discoveryMatthew G Soars, Patrick Barton, Manfred Ismair, et al.
Pharmacology Research & Perspectives|October 8, 2016
Evaluation of a novel PXR-knockout in HepaRG<sup>™</sup> cellsBeth Williamson, Mathias Lorbeer, Michael D Mitchell, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 2, 2011
Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorptionStuart W Paine, Karelle Ménochet, Rebecca Denton, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 9, 2006
Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytesDermot F McGinnity, Amanda J Berry, Jane R Kenny, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 20, 2002
CYP3A4 active site volume modification by mutagenesis of leucine 211Stephen M Fowler, John M Taylor, Thomas Friedberg, et al.
Pageof 5